Robert M. Brenner
Directeur Technique/Scientifique/R&D chez VERA THERAPEUTICS, INC.
Profil
Robert M.
Brenner is currently the Chief Medical Officer at Vera Therapeutics, Inc. He previously held positions as the President & Chief Executive Officer at AlloCure, Inc. in 2010, the Executive Director-Nephrology Medical Affairs at Amgen, Inc. from 1999 to 2008, the Senior Vice President-Medical Affairs at AMAG Pharmaceuticals, Inc. from 2008 to 2010, the Chief Medical Officer at Orionis Biosciences, Inc. from 2015 to 2018, and the Executive VP-Research & Development at Codiak BioSciences, Inc. from 2018 to 2019.
He obtained his undergraduate degree from The Johns Hopkins University and his doctorate degree from Albert Einstein College of Medicine, Inc.
Postes actifs de Robert M. Brenner
| Sociétés | Poste | Début |
|---|---|---|
| VERA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 08/01/2023 |
Anciens postes connus de Robert M. Brenner
| Sociétés | Poste | Fin |
|---|---|---|
| CODIAK BIOSCIENCES | Directeur Technique/Scientifique/R&D | 01/03/2019 |
Orionis Biosciences, Inc.
 Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Orionis Biosciences, Inc. engages in operation of an biotechnology company that specializes in drug discovery. It offers A-Kine biologics and Allo-Glue, a small molecule platform with applications to the reprogramming of disease states. The company was founded by Nikolai Kley and Jan Tavernier and is headquartered in Waltham, MA. | Directeur Technique/Scientifique/R&D | 01/09/2018 |
| AMAG PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 04/06/2010 |
| AMGEN INC. | Corporate Officer/Principal | 01/05/2008 |
AlloCure, Inc.
 AlloCure, Inc. BiotechnologyHealth Technology AlloCure, Inc. develops cell therapies for the treatment of kidney diseases. It engages in developing allogeneic mesenchymal stem cell therapy for acute kidney injury. The company was founded in 2008 and is headquartered in Burlington, MA. | Directeur Général | - |
Formation de Robert M. Brenner
| The Johns Hopkins University | Undergraduate Degree |
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| VERA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
AlloCure, Inc.
AlloCure, Inc. BiotechnologyHealth Technology AlloCure, Inc. develops cell therapies for the treatment of kidney diseases. It engages in developing allogeneic mesenchymal stem cell therapy for acute kidney injury. The company was founded in 2008 and is headquartered in Burlington, MA. | Health Technology |
Orionis Biosciences, Inc.
Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Orionis Biosciences, Inc. engages in operation of an biotechnology company that specializes in drug discovery. It offers A-Kine biologics and Allo-Glue, a small molecule platform with applications to the reprogramming of disease states. The company was founded by Nikolai Kley and Jan Tavernier and is headquartered in Waltham, MA. | Technology Services |
Codiak BioSciences, Inc.
 Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. Codiak BioSciences was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA. | Health Technology |
